Abstract
Spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominant ataxia worldwide. First targeted gene therapy trials have started, offering the intriguing scenario of preventive treatment. SCA3 is associated with progressive regional brain atrophy that starts before clinical manifestation. We aimed to identify the spatiotemporal progression pattern of brain atrophy of SCA3 with a focus on early disease stages.
T1-weighted MRI scans of 300 SCA3 mutation carriers and 317 controls were analyzed. Subtype and Stage Inference (SuStaIn) was used to identify the sequence of volume loss across selected brain regions.
We observed one distinct sequence of brain atrophy events in SCA3 without evidence for the existence of alternative cascades. Atrophy started in the most caudal parts of the brainstem. Almost all preataxic SCA3 mutation carriers clustered in the first atrophy stages. Certainty of sequence estimation was highest for early atrophy stages with prominent involvement of the pons and cerebellar white matter.
Brain atrophy in SCA3 follows a clear and distinct sequence ascending from the lower brainstem with an early involvement of white matter. Knowledge of this sequence might support the stratification of SCA3 mutation carriers with an imminent clinical onset for early interventions.
- Disease staging
- SCA3
- Imaging Biomaker
- MRI
Competing Interest Statement
JF received consultancy frees from Vico Therapeutics, unrelated to the present manuscript, and funding from the Advanced Clinician Scientist Programme (ACCENT, funding code 01EO2107, the ACCENT Program is funded by the German Federal Ministry of Education and Research (BMBF)) as well as a fellow of the Hertie Network of Excellence in Clinical Neuroscience. TK is receiving research support from the German Federal Ministry of Education and Research (BMBF) and Servier.
Funding Statement
This publication is an outcome of ESMI, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu). The project is supported through the following funding organisations under the aegis of JPND: Germany, Federal Ministry of Education and Research (BMBF; funding codes 01ED1602A/B); Netherlands, The Netherlands Organisation for Health Research and Development; United Kingdom, Medical Res earch Council (MR/N028767/1). At the US sites this work was in part supported by the National Ataxia Foundation and the National Institute of Neurological Disorders and Stroke (NINDS) grant R01NS080816. The Center for Magnetic Resonance Research is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) grant P41 EB027061, the Institutional Center Cores for Advanced Neuroimaging award P30 NS076408 and S10 OD017974 grant. JF received consultancy frees from Vico Therapeutics, unrelated to the present manuscript, and funding from the Advanced Clinician Scientist Programme (ACCENT, funding code 01EO2107, the ACCENT Program is funded by the German Federal Ministry of Education and Research (BMBF)) as well as a fellow of the Hertie Network of Excellence in Clinical Neuroscience. TK is receiving research support from the German Federal Ministry of Education and Research (BMBF) and Servier. MCF is funded by Friedreichs research alliance (FARA, USA) and Fundacao de Amparo a pesquisa do Estado de Sao Paulo (grants # 2021/06739-4 and 2013/07559-3). TJRR is funded by Friedreichs research alliance (FARA, USA). No further conflicting interests were disclosed related to this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the University Hospital Bonn gave ethical approval for this work. Ethics committee/IRB of the University of Campinas gave ethical approval for this work. In addition, the ethics committee/IRB of the Xiangya Hospital, Central South University in China (Reference number: 202310206) gave ethical approval for this work. Ethics committee/IRB of the Radboud University Medical Center Nijmegen gave ethical approval for this work. Ethics committee/IRB of the Salpetrier University Hospital Paris gave ethical approval for this work. Ethics committee/IRB of the University Hospital Tuebingen gave ethical approval for this work. Ethics committee/IRB of the UCL London gave ethical approval for this work.Ethics committee/IRB of the University of Minnesota gave ethical approval for this work. Ehtics committee/IRB of the University Hospital Essen gave ethical approval for this work. Ethics committee/IRB of the University Hospital Heidelberg gave ethical approval for this work. Ethics committee/IRB of the University Medical Center Groningen gave ethical approval for this work. Ethics committee/IRB of the Johns Hopkins University School of Medicine, Baltimore, gave ethical approval for this work, as well as the Massachusetts General Hospital. Ethics committee/IRB of the RWTH Aachen gave ethical approval for this work. Ethics committee/IRB of the University of Cantabria gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised version with the correction of a typo of in the Surname of the first author.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
